Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MRNA-4157 by Moderna for Metastatic Melanoma: Likelihood of Approval
MRNA-4157 is under clinical development by Moderna and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...
MRNA-4157 by Moderna for Gastric Cancer: Likelihood of Approval
MRNA-4157 is under clinical development by Moderna and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...
MRNA-4157 by Moderna for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
MRNA-4157 is under clinical development by Moderna and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
MRNA-4157 by Moderna for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
MRNA-4157 is under clinical development by Moderna and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to...
MRNA-4157 by Moderna for Renal Cell Carcinoma: Likelihood of Approval
MRNA-4157 is under clinical development by Moderna and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase...
MRNA-4157 by Moderna for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
MRNA-4157 is under clinical development by Moderna and currently in Phase III for Squamous Non-Small Cell Lung Cancer. According to...
MRNA-4157 by Moderna for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
MRNA-4157 is under clinical development by Moderna and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According...
MRNA-4157 by Moderna for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
MRNA-4157 is under clinical development by Moderna and currently in Phase III for Cutaneous Squamous Cell Carcinoma (cSCC). According to...